- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04303481
The Effect of Consuming Enzymes and Prebiotics on Body Composition and Blood Biochemical Index
10. mars 2020 oppdatert av: TCI Co., Ltd.
To assess the effects of consuming enzymes and prebiotics on improvement of weight loss and biochemical parameters
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
88
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Neipu Township
-
Pingtung, Neipu Township, Taiwan, 91201
- National Pingtung University of Science and Technology
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 50 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Male or female aged between 20 and 50 years old
- Body mass index (BMI) ≥ 22 (kg/m^2) or body fat mass: male > 25%, female > 30%
- Prohibitions on other nutritional supplements (probiotics and prebiotics) before two weeks of the study
- Abidance by the similar diet and exercise habits over the study.
Exclusion Criteria:
- Pregnant or breastfeeding woman
- Menopausal woman
- Diabetes mellitus
- Implementation in weight loss programs before a half year of this study
- Metabolic disorders
- Kidney diseases
- Liver diseases
- Cardiovascular diseases
- Nervous system diseases
- Gastrointestinal diseases
- Heavy drinking or constant drug use.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: normal diet
|
Control
|
|
Eksperimentell: weight loss program kit
|
Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks [i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, and Botanical Liquid Sachet.
|
|
Eksperimentell: weight loss program kit with A. muciniphila prebiotics
|
Subjects should adhere to the eating plan, which contained the following kit components : four flavors of collagen drinks [i.e., Caviar Collagen Enzyme Drink, Collagen Enzyme Drinks (Peach Taste), Collagen Enzyme Drinks (Grape Fruit Taste), Saussurea involucrata Enzyme Drink (Litchi Taste)], six flavors of mike shakes (i.e., Corn Soup Mike Shake, Strawberry Mike Shake, Chocolate Mike Shake, Vanilla Mike Shake, Banana Mike Shakes, Matcha Mike Shakes), Fruit and Vegitable Congee, Botanical Liquid Sachet, and Probiotics Liquid Sachet
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of body fat mass
Tidsramme: Months 0, 1 and 2
|
The body fat mass (kg) was assessed by InBody770.
|
Months 0, 1 and 2
|
|
The change of Triglyceride
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of Triglyceride
|
Months 0, 1 and 2
|
|
The change of Total cholestrol
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of Total cholestrol
|
Months 0, 1 and 2
|
|
The change of HDL-cholestrol
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of HDL-cholestrol
|
Months 0, 1 and 2
|
|
The change of LDL-cholestrol
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of LDL-cholestrol
|
Months 0, 1 and 2
|
|
Fecal microbiome analysis
Tidsramme: Months 0, 1 and 2
|
Firmicutes, Bacteroidetes, Lactobucillius, and A. muciniphila were quantified by quantitative PCR.
|
Months 0, 1 and 2
|
|
The change of body mass index (BMI)
Tidsramme: Months 0, 1 and 2
|
BMI is a measurement of a person's leanness or corpulence based on their height and weight, and is intended to quantify tissue mass.The body mass index (BMI, kg/m^2) and body mass (kg) were assessed by InBody770.
|
Months 0, 1 and 2
|
|
The change of body fat percentage
Tidsramme: Months 0, 1 and 2
|
The body fat percentage (%) was assessed by InBody770.
|
Months 0, 1 and 2
|
|
The change of visceral fat
Tidsramme: Months 0, 1 and 2
|
The visceral fat (10 cm^2) was assessed by InBody770.
|
Months 0, 1 and 2
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The change of fasting glycemia
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of fasting glycemia
|
Months 0, 1 and 2
|
|
The change of aspartate aminotransferase
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of aspartate aminotransferase
|
Months 0, 1 and 2
|
|
The change of alanine aminotransferase
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of alanine aminotransferase
|
Months 0, 1 and 2
|
|
The change of albumin
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of albumin
|
Months 0, 1 and 2
|
|
The change of creatine
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of creatine
|
Months 0, 1 and 2
|
|
The change of uric acid
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of uric acid
|
Months 0, 1 and 2
|
|
The change of white blood cell
Tidsramme: Months 0, 1 and 2
|
Venous blood was sampled to measure concentrations of white blood cell
|
Months 0, 1 and 2
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
10. august 2019
Primær fullføring (Faktiske)
3. november 2019
Studiet fullført (Faktiske)
31. desember 2019
Datoer for studieregistrering
Først innsendt
3. mars 2020
Først innsendt som oppfylte QC-kriteriene
10. mars 2020
Først lagt ut (Faktiske)
11. mars 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
11. mars 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. mars 2020
Sist bekreftet
1. mars 2020
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 19-062-A
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .